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Abstract
Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK 
inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been 
associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The purpose of this research was to use a 
novel planar sectioning technique to determine CDK expression profiles in the ex vivo human retina with the aim of iden-
tifying isoforms responsible for CDK retinotoxicity. Four CDK isoforms (CDK11, 16, 17 and 18) were selected as a result 
of  IC50 data comparing neurotoxic (AG-012986 and NVP-1) and non-neurotoxic (dinaciclib and NVP-2) CDK inhibitors, 
with  IC50s at CDK11 showing a clear difference between the neurotoxic and non-neurotoxic drugs. CDK11 was maximally 
expressed in the photoreceptor layer, whereas CDK16, 17 and 18 showed maximal expression in the inner nuclear layer. 
CDK5 (an isoform associated with retinal homeostasis) was maximally expressed in the retinal ganglion cell layer. Apart 
from CDK18, each isoform showed expression in the photoreceptor layer. The human Müller cell line MIO-M1 expressed 
CDK5, 11, 16 and 17 and AG-01298 (0.02–60 µM) caused a dose-dependent increase in MIO-M1 cell death. In conclusion, 
CDK11 appears the most likely candidate for mediation of photoreceptor toxicity. RNA profiling can be used to determine 
the distribution of genes of interest in relation to retinal toxicity in the human retina.
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Introduction
Cyclin-dependent kinases (CDKs) are a large family (> 20) 
of serine/threonine protein kinases which play fundamen-
tal and complex roles within the cell (Malumbres 2014; 
Malumbres and Barbacid 2005). They are primarily associ-
ated with driving the cellular processes and signals which 
coordinate progression through the cell cycle. CDKs, as the 
name suggests, depend on cyclins for activation, forming 
heterodimeric complexes to enable activity. Cyclins are 
synthesised and degraded throughout the cell cycle which 
regulates the activity of CDKs with well-documented roles 
for CDKs 1, 2, 4 and 6 (Malumbres 2014; Malumbres and 
Barbacid 2005). Interestingly, CDK expression is present 
in post-mitotic cells and CDKs are known to play roles out-
side of the cell cycle (Hydbring et al. 2016; Lim and Kaldis 
2013) including control over other important cell events 
such as differentiation and cell death. They also have a cen-
tral involvement in transcriptional regulation, for example, 
CDKs 7, 8 and 9 regulate the activity of RNA polymerase II 
(Bregman et al. 2000; Malumbres 2014; Parry et al. 2010). 
CDK11 is involved in transcription and RNA process-
ing events (Hu et al. 2003), but also is implicated in other 
cellular processes including autophagy (Wilkinson et al. 
2011). In post-mitotic cells, much research has focussed 
on CDK5, which is atypical in that it is not activated by 
cyclins, is cytoplasmic/plasma membrane associated rather 
than nuclear and also has its highest expression in neurons, 
classical terminally differentiated cells. In neurons, CDK5 is 
associated with synaptic vesicle turnover, neurotransmitter 
release, post-synaptic signalling, synaptogenesis and synap-
tic plasticity, as well as regulation of cell survival/cell death 
pathways (Su and Tsai 2011). It is also implicated in the 
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regulation of phototransduction in the retina (Hayashi et al. 
2000) and is involved in retinal development (Hirooka et al. 
1996; Nakayama et al. 1999). CDKs 16, 17 and 18 are within 
the CDK5 family (Malumbres 2014) and are also known to 
be expressed in neurons (Shimizu et al. 2014; Hirose et al. 
1997; Herskovits and Davies 2006), although their role has 
been less well defined.
Recently, CDK inhibitors have become of interest due 
to their potential to be used as cancer therapeutics (Li et al. 
2016). Given their fundamental role in cell cycle control, 
CDK dysregulation is a common feature in cancer cells and 
they are over-expressed in many tumours (Nemunaitis et al. 
2013). First-generation CDK inhibitors were pan-selective 
(Li et  al. 2016) and these were effective in pre-clinical 
studies, with potent anti-proliferative activity. However, as 
might be expected given the extensive roles of the CDK 
family, they were associated with toxicity. For example, 
the pan-CDK inhibitor AG012986 was found to be highly 
neurotoxic, with both peripheral (sciatic nerve toxicity) and 
central (retinotoxicity) effects found in mice (Illanes et al. 
2006). Clearly, such toxicity would limit therapeutic use; 
whether such toxicity would be expected to occur in humans 
is a key consideration. It is also important to understand 
which CDKs are involved in mediating neurotoxicity to pre-
dict whether more selective inhibitors would exhibit similar 
neurotoxic effects. Second-generation CDK inhibitors have 
been developed which have greater selectivity and some are 
showing therapeutic potential, with numerous clinical trials 
ongoing. One drug, palbociclib (a CDK4/6 inhibitor), has 
been FDA approved, albeit with restricted clinical indica-
tions (Zhang et al. 2017). Highly selective CDK9 inhibi-
tors are also of interest as cancer therapeutics (Franco et al. 
2018), with proposed mechanisms via the regulation of RNA 
Polymerase II (Huang et al. 2014; Lu et al. 2015; Okuda 
et al. 2016; Rahl et al. 2010; Samarakkody et al. 2015). 
NVP-1 and NVP-2 are selective CDK9 inhibitors (Barsanti 
2011) which, interestingly, display differential neurotoxicity 
(Sutton 2014). Other inhibitors, for example dinaciclib, have 
a wider selectivity, which may prove important in terms of 
efficacy given the significant redundancy observed in CDKs 
in relation to cell cycle control (Di Giovanni et al. 2016).
The retina is responsible for phototransduction, trans-
forming light energy into neuronal signals which are in 
turn processed by the brain to enable vision. The retina is 
divided into layers including three distinct nuclear layers 
(the inner and outer nuclear layer and the ganglion cell layer) 
and two synaptic layers (the inner and outer plexiform lay-
ers) (Fig. 1). The ganglion cell layer is dominated by retinal 
ganglion cells which are responsible for the transmission of 
information from the retina to the brain (Sanes and Masland 
2015). The axons of the retinal ganglion cells make up the 
nerve fibre layer (the innermost retinal layer) and leave the 
eye at the optic nerve head. The next nuclear layer is the 
inner nuclear layer which consists of the cell bodies of sev-
eral retinal cells including Müller cells (glial cells responsi-
ble for physical and metabolic support of the retinal neurons) 
(Bringmann et al. 2006; Reichenbach and Bringmann 2013), 
bipolar cells (transmit signals from the photoreceptors to the 
ganglion cells) (Euler et al. 2014), horizontal cells (modu-
late signalling between photoreceptors and bipolar cells) 
(Poche and Reese 2009), amacrine cells (provide inhibitory 
modulation of information to bipolar cells) (Forrester 2007), 
interplexiform neurons (provide long range feedback with 
processes which extend into both the inner plexiform layer 
and the outer plexiform layer) (Jiang and Shen 2010) and 
some displaced ganglion cells. The most posterior nuclear 
layer is the outer nuclear layer which consists of cell bodies 
from rod and cone photoreceptors, the cells responsible for 
converting light into a neural signal (Forrester 2007).
The aim of these experiments was to investigate CDK 
expression in the human retina. Based on  IC50 data, predic-
tions were made regarding the CDKs which may be involved 
in neurotoxicity. The expression of these was investigated in 
the human retina using a novel mRNA expression profiling 
technique, and the results compared known retinal cell mark-
ers to determine regions of high expression. It also aimed 
to investigate toxicity of AG-012986 in human Müller cells 
in relation to CDK expression. Revealing the localisation 
of CDK expression within the retina may help determine 
Fig. 1  Light micrograph of human retina. NFL nerve fibre layer, GCL 
ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer, 
OPL outer plexiform layer, ONL outer nuclear layer, POS photorecep-
tor outer segments
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the isoform/s responsible for the retinal toxicity found with 
the CDK inhibitor AG-012986 and help inform the future 
development of CDK inhibitors to avoid retinotoxicity. The 
development and characterisation of such techniques may 
also prove useful in future investigations of other targets 
relating to retinal toxicity.
Materials and methods
CDK inhibitor affinity
The CDK inhibitors NVP-1, NVP-2, dinaciclib and 
AG012986 were synthesised in house by AstraZeneca. The 
 IC50s of the CDK inhibitors towards the CDKs of interest 
were assessed by DiscoverX (Eurofins DiscoverX Corpora-
tion, Fremont, USA) by means of their KINOMEscan profil-
ing service. KINOMEscan utilizes three components which 
are combined to form a competition binding assay: DNA-
tagged kinase, immobilized ligand and the CDK inhibitor of 
choice. The ability of the CDK inhibitor to compete with the 
immobilized ligand is then assessed via qPCR, as described 
by Fabian et al. (2015).
Human retinal explant dissection
The East Anglian Eye Bank provided donor human eyes 
within 24 h post mortem. The cornea had been removed for 
transplantation and the remainder had consent for research. 
The research was conducted with full ethical approval under 
the tenets of the declaration of Helsinki. Only eyes with no 
known retinal pathology/injury were utilised for research. 
In total, 16 post mortem donor eyes were used in this study 
from donors aged between 41 and 92 years old. The retina 
was dissected as described previously (Niyadurupola et al. 
2011; Osborne et al. 2016). Briefly, the lens and the iris were 
removed by a circumferential incision. The weight of the 
vitreous was then used to detach the retina from the RPE and 
an incision made around the optic nerve head to fully detach 
the retina and vitreous from the RPE and sclera. The vitreous 
was detached from the retina and small incisions made at 
periphery to allow the retina to flatten. The retinal prepara-
tion was placed over an extraction template (Osborne et al. 
2016) using the optic nerve and fovea as reference points, 
and the macula and five paramacular explants removed using 
a 4 mm trephine (Biomedical Research Instruments, MD, 
USA). Paramacula sample 3 (temporal to the macula) was 
used for explant analysis. The explants were either snap fro-
zen in liquid nitrogen for RNA extraction or prepared for 
planar sectioning.
Planar retinal sectioning
Planar sectioning was performed as described previously 
(Niyadurupola et  al. 2013). Briefly, macular and para-
macular explants were dissected from donor eyes, removed 
from the culture dish using filter paper and mounted onto 
a flattened surface of frozen optimal cutting temperature 
compound (OCT) (Sakura Finetek, Zoeterwoude, Nether-
lands). Another layer of OCT was then applied on top of 
the mounted retinal explant and frozen. A Bright OTF 5000 
cryostat (Bright instruments, Huntingdon, UK) was used to 
cut 20 µm sections which were collected in 1.5 ml Eppen-
dorfs, snap frozen in liquid nitrogen and stored at − 80 °C.
Quantitative real‑time PCR (qRT‑PCR)
RNA was extracted from retinal explants using the RNeasy 
Mini Kit (Qiagen, Crawley, UK) or planar sections using the 
RNeasy Micro Kit (Qiagen, Crawley, UK). The concentra-
tion and quality of RNA was assessed using a Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, USA). The RNA was then reverse transcribed 
to cDNA using Superscript™ II, dNTP mix and random 
primers (Invitrogen, Paisley, UK). 5 ng of cDNA was mixed 
with Mastermix (Applied Biosystems, Warrington, UK) plus 
probes/primers (see Table 1) and mRNA expression assessed 
using Taqman qRT-PCR (ABI Prism 7700 Sequence Detec-
tion System; Applied Biosystems, Warrington, UK). Expres-
sion in explants was normalised to the geometric mean of 
the house-keeping genes topoisomerase DNA I (TOP1) and 
cytochrome c-1 (CYC1) (Niyadurupola et al. 2011). Since 
the expression of house-keeping genes varied across the ret-
ina, expression in planar sections was normalised to the sec-
tion with the highest expression (Niyadurupola et al. 2013). 
Expression in samples from different donors was aligned by 
superimposing the expression profile for RCVRN.
Cell culture
The human Müller cell line (MIO-M1) was kindly provided 
by Professor Astrid Limb (University College London, UK) 
and is derived from a primary culture of human retinal cells 
(Limb et al. 2002). MIO-M1 cells were routinely cultured in 
DMEM GLUTAMAX medium (ThermoFisher, Loughbor-
ough, UK) with 10% FBS (ThermoFisher, Loughborough, 
UK), and 50 µg/l Pen-Strep (ThermoFisher, Loughbor-
ough, UK) in a humidified incubator (35 °C; 95% air; 5% 
 CO2). For assessment of cell viability/cell death, cells were 
cultured in 96 well plates (ThermoFisher, Loughborough 
UK). Cells were plated in serum-supplemented medium to 
reach 90% confluency, then serum-starved for 24 h prior to 
exposure to experimental conditions. AG012986 was dis-
solved in DMSO and diluted in SF medium to the desired 
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concentration with a DMSO content of less than 0.1% and 
incubated with the cells for 24 h.
Assessment of cell death and cell viability
Following incubation in experimental conditions for 24 h, 
100 µl of media was removed for analysis of cell death using 
the LDH assay according to manufacturer’s instructions 
(Roche, Burgess Hill, UK). The absorbance was measured 
at 490 nm (BMG labtech platereader, Aylesbury, UK). Back-
ground was subtracted and data expressed as fold-change 
relative to control levels. To assess cell viability, the remain-
ing medium was aspirated and cell viability was assessed 
using the CellTiter  96® AQueous One Solution Cell Prolif-
eration Assay (MTS assay) (Promega, Southampton, UK). 
The assay was performed according to the manufacturer’s 
instructions and the plate measured at 490 nm (BMG labtech 
platereader, Aylesbury, UK). Background was subtracted 
and data expressed relative to control (%). Four independ-
ent replicates of each experiment were carried out.
Results
Selectivity of four CDK inhibitors to CDK isoforms
Initial experiments compared the  IC50s of the CDK inhibi-
tors NVP1, NVP2, dinaciclib and AG-012986 for a range 
of CDKs (Fig. 2). These inhibitors were selected due to 
their neurotoxicity profiles; both AG-012986 and NVP-1 
have reported neurotoxicity (in vivo; mouse) (Illanes 
et al. 2006; Sutton 2014), whereas NVP-2 and dinaciclib 
have no reported neurotoxicity. The neurotoxic inhibitor 
NVP-1 displayed an approximate tenfold lower  IC50 for 
CDKs 11, 16, 17 and 18 compared to the non-neurotoxic 
NVP-2. This implicates these CDK isoforms in mediation 
Table 1  List of PCR primers/
probes Primer/probe Number Reporter Source
Topoisomerase (TOP1) FAM Primer Design, Southampton, UK
Cytochrome C1 (CYC1) FAM Primer Design, Southampton, UK
THY1 Hs00174816_m1 FAM Applied Biosystems, Warrington, UK
Protein kinase C alpha Hs00925193_m1 FAM Applied Biosystems, Warrington, UK
Choline acetyltransferase Hs00252848_m1 FAM Applied Biosystems, Warrington, UK
Calbindin Hs01077197_m1 FAM Applied Biosystems, Warrington, UK
Retinaldehyde binding protein 1 Hs00165632_m1 FAM Applied Biosystems, Warrington, UK
Recoverin Hs00610056_m1 FAM Applied Biosystems, Warrington, UK
Cyclin-dependent kinase 5 Hs00358991_g1 FAM Applied Biosystems, Warrington, UK
Cyclin-dependent kinase 11A/B Hs02341397_m1 FAM Applied Biosystems, Warrington, UK
Cyclin-dependent kinase 16 Hs00178837_m1 FAM Applied Biosystems, Warrington, UK
Cyclin-dependent kinase 17 Hs00176839_m1 FAM Applied Biosystems, Warrington, UK
Cyclin-dependent kinase 18 Hs00384387_m1 FAM Applied Biosystems, Warrington, UK
Fig. 2  IC50s of four CDK inhibitors towards different CDK isoforms. 
Green symbols (A and B) represent two CDK inhibitors without any 
recorded neurotoxic side effects, red symbols (C and D) represent two 
CDK inhibitors with recorded neurotoxicity. A NVP-2, B dinaciclib, 
C NVP-1, D AG-012986. (Color figure online)
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of neurotoxicity. Interestingly, AG-012986, which is also 
neurotoxic, possesses a similar  IC50 to NVP-2 for CDK 11, 
16 and 17. Dinaciclib, which has no reported neurotoxicity, 
had a markedly different profile to the other CDK inhibitors 
investigated, with high potency  (IC50 < 100 nM) for all of the 
CDKs tested apart from CDKs 11, 16, 17 and 18 (identified 
above) plus CDKs 8 and 19.
These data indicate that CDK11 may be the most inter-
esting isoform to investigate as a possible candidate for 
mediation of retinotoxicity, with CDK 16, 17 and 18 also of 
potential interest; these CDKs were therefore selected for 
further investigation. CDK5 was also investigated further 
due to its known roles in supporting neuronal and RGC sur-
vival (Cheung et al. 2008), its involvement in RGC death in 
glaucoma (Chen et al. 2011) and potential role in phototrans-
duction in the retina (Matsuura et al. 2000).
Expression of retinal cell markers in macula 
and paramacula explants
Retinal ganglion cells (RGCs) are found at highest abun-
dance in the macular region of the retina. Accordingly, the 
RGC marker THY1 (Fig. 3A) displayed significantly higher 
expression in macula samples compared to the paramacula. 
Conversely, rod ON bipolar cells are in low abundance in 
the macula and the marker for these cells, PRKCA (Fig. 3B) 
displayed significantly lower expression in the macula com-
pared to the paramacula. The horizontal cell marker CALB1 
and the amacrine cell marker CHAT (Fig. 3C, D, respec-
tively) displayed little difference in expression between the 
paramacula and macula samples, whereas the Müller cell 
marker RLBP1 (Fig. 3E) showed significantly lower expres-
sion in the macula. The marker of photoreceptors RCVRN 
(Fig. 3F) showed no significant difference in expression 
between the paramacula and macula, however, a trend of 
lower expression in the macula was found. The distributions 
of retinal cell markers were consistent with the known distri-
bution of retinal cells in the macular and paramacular retina, 
demonstrating that this technique could be useful to indicate 
the distribution of the CDKs of interest within retinal cells.
CDK5, 11, 16, 17 and 18 transcripts were detected in the 
human retina (Fig. 4). When comparing expression between 
the macula and paramacula, CDK5 and CDK18 displayed 
differences in expression between the two regions, with 
CDK5 showing greater expression in the macula (Fig. 4A) 
and CDK18 showing the opposite distribution (Fig. 4E). 
These data suggest that CDK5 and 18 are differentially dis-
tributed in the retina which may relate to expression being 
Fig. 3  Expression of A THY1, B PRKCA, C CALB1, D CHAT, E RLBP1, and F RCVRN mRNA in human macula and paramacula retina relative 
TOP1 and CYC1. Mean ± SEM (n = 4) *significant difference from the control (unpaired T test) (P < 0.05)
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localised to different cell types that show similar distribu-
tions (Fig. 3).
Expression profiles of CDKs compared to cell‑specific 
markers in the macula and paramacula human 
retina
To investigate the distribution of CDK transcripts within the 
layers of the human retina, expression profiling was used 
(Niyadurupola et al. 2013). The distribution of cell specific 
markers was first determined in planar-sectioned macula 
and paramacula retina (Fig. 5). Peak expression of THY1 
was observed in the inner retina in both macula and para-
macula retina, corresponding to expression in the ganglion 
cell layer, as would be anticipated for a RGC marker. In the 
mid-section, corresponding to the inner nuclear layer (INL), 
there was peak expression of the markers RLBP1, CALB1 
and PRKCA. Expression of these markers was similar in both 
macula and paramacula samples and displayed low levels 
of expression in the outer retina, reaching peak expression 
in the inner nuclear layer, followed by a decrease in expres-
sion through the inner retina (GCL). CHAT expression was 
baseline in the outer retina of both macula and paramacula 
samples. However in the macula, peak expression was seen 
in sections associated with INL, whereas peak expression in 
the paramacula explant did not occur until the ganglion cell 
layer. As would be anticipated for a marker of photorecep-
tors, the outermost retina, corresponding to the outer nuclear 
layer (ONL), displayed highest expression of RCVRN both 
in the macula and paramacula sections. Peak expression in 
the ONL was followed by a decrease towards the INL and 
baseline expression in the GCL.
The expression profile of the CDKs of interest was 
determined in relation to the distribution of the known 
retinal cell markers. Figure 6 shows the macula and para-
macula expression profiles of CDK5, 11, 16, 17 and 18. 
Profiles of THY1, PRKCA and RCVRN in the same samples 
identify the ganglion cell layer, the inner nuclear layer 
and the outer nuclear layer, respectively. CDK5 expression 
peaked in the GCL of both the macula and paramacula 
retina. However, in the macula, there was little variation 
across the different layers, whereas, in the paramacula, 
expression was greater than twofold higher in the GCL 
compared to the outer layers. CDK11 displayed peak 
expression in the ONL in both macula and paramacula 
retina, with expression being approximately twofold and 
fourfold higher in the ONL compared to the GCL in the 
macula and paramacula, respectively. CDK16 displayed 
low expression in the outer nuclear layer of the macula, 
followed by increasing expression in the inner nuclear 
Fig. 4  Expression of A CDK5, B CDK11, C CDK16, D CDK17 and E CDK18 mRNA in human macula and paramacula retina relative to house-
keeping genes TOP1 and CYC1. Mean ± SEM (n = 4) *significant difference from the control (unpaired T test) (P < 0.05)
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layer and remaining high throughout the GCL. In the para-
macula, there was also low expression in the outer nuclear 
layer, however, this was followed by peak expression in the 
inner nuclear layer and low expression in the ganglion cell 
layer. CDK17 and CDK18 displayed a similar pattern of 
expression in both macula and paramacula samples, with 
low expression in the ONL (close to no expression with 
CDK18), followed by peak expression in the INL, and low 
expression in the GCL.
Effect of the CDK inhibitor AG‑012986 on Müller cell 
viability
To investigate retinal cell toxicity, the effects of the CDK 
inhibitor AG-012986 on Müller cell viability was inves-
tigated using the MIO-M1 cell line (Limb et al. 2002). 
In addition, expression of CDK5, 11, 16, 17 and 18 was 
assessed. It was found that AG-012986 was toxic to MIO-
M1 cells, with a dose-dependent decrease in cell viability 
Fig. 5  Expression profiles of 
THY1, CHAT, RLBP1, CALB1, 
PRKCA and RCVRN in macula 
and paramacula human retina. 
The outer nuclear layer is 
represented by the light grey 
bar, the inner nuclear layer by 
the medium grey bar and the 
ganglion cell layer by the dark 
grey bar. Mean ± SEM (n = 4)
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Fig. 6  Expression profile 
of CDK5, CDK11, CDK16, 
CDK17 and CDK18 mRNA in 
macula and paramacula sam-
ples. Profiles of THY1, PRKCA 
and RCVRN are shown for 
comparison. The outer nuclear 
layer is represented by the light 
grey bar, the inner nuclear layer 
by the medium grey bar and the 
ganglion cell layer by the dark 
grey bar. Mean ± SEM (n = 4)
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detected using the MTS proliferation assay, and a corre-
sponding increase in LDH release (Fig. 7). In each case, a 
significant effect was achieved at a concentration of 200 nM 
AG-012986, and a maximal response achieved at 500 nM. 
The maximal decrease in viability was approximately 25%, 
i.e., full toxicity was not observed. MIO-M1 cells expressed 
CDK5, 11, 16 and 17, but there was very little expression 
of CDK18 (Fig. 8).
Discussion
Cyclin-dependant kinases are potential targets for cancer 
therapeutics and exploitation of CDK inhibitors is of major 
interest. Chemotherapy drugs that target rapidly dividing 
cancer cells have detrimental side effects on rapidly dividing 
non-cancer cells. This is true for CDK inhibitors (Lee and 
Jessen 2012), for example, leukopenia is a dose-limiting fac-
tor for dinaciclib (Mita et al. 2014; Stephenson et al. 2014) 
and flavopiridol (Luke et al. 2012; Jones et al. 2014). How-
ever, the pan-CDK inhibitor AG-0129896 also showed an 
unexpected toxic effect, with sciatic nerve and photoreceptor 
toxicity being found when AG-012986 toxicity was assessed 
in mice (Illanes et al. 2006). Interestingly, both of these cell 
types have an arrested cell cycle, yet are susceptible to the 
effects of CDK inhibition. Potential toxicity is an important 
consideration when developing CDK inhibitors as cancer 
therapies; a better understanding of mechanisms would be 
beneficial.
Initial experiments determined which CDKs were the 
most interesting in terms of mediation of neurotoxicity. Four 
different CDK inhibitors were compared, two had reported 
neurotoxicity, whereas two had no reported neurotoxic-
ity. Their  IC50s for a range of CDKs were assessed. Two 
CDK families of interest were identified: the CDC2L family 
(CDK11A and 11B) and the PCTK family (CDK16, 17 and 
18). CDK5 was also investigated due to its well-documented 
role in neuronal homeostasis (Su and Tsai 2011).
To investigate localization of CDKs in the human retina, 
the expression of known retinal cell markers was first char-
acterised. Expression of cell-specific markers was inves-
tigated topographically in macula and paramacula retina, 
followed by determination of the expression profiles of the 
cellular markers in planar-sectioned macula and paramacula 
retina. Whole explant mRNA analysis of the cell-specific 
markers showed the ganglion cell marker THY1 to have 
significantly higher expression in the macula compared to 
the paramacula. RGCs are present at a higher density in the 
macula compared to paramacula explants (Niyadurupola 
et al. 2011), demonstrating that this technique can provide 
information regarding the distribution of retinal cell types. 
Fig. 7  LDH release and cell viability of MIO-M1 cells in response to 
24 h treatment with AG-012986. a LDH release from MIO-M1 cells 
in response to the pan-CDK inhibitor AG-012986. b % control cell 
viability of MIO-M1 cells in response to differing concentrations 
of AG-012986. *Significant difference from the control (one way 
ANOVA with Dunnet’s post hoc test) (P < 0.05)
Fig. 8  Expression of CDK5, CDK11, CDK16, CDK17 and CDK18 
mRNA in MIO-M1 cells relative to TOP1 and CYC1. Mean ± SEM 
(n = 3)
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Planar sectioning confirmed peak expression of THY-1 to 
be localised to the GCL. The inner nuclear layer markers 
CHAT (amacrine cells) and CALB1 (horizontal cells) had 
equivalent expression in paramacula and macula retina, 
whereas the inner nuclear layer markers PRKCA (rod ON 
bipolar cells) and RLBP (Müller cells) had significantly 
lower expression in the macula compared to the paramacula 
retina. The lower expression of PRKCA in macula samples 
compared to paramacula samples can be explained by the 
location of rod ON bipolar cells. Rod ON bipolar cells only 
appear approximately 1 mm away from the fovea (Lameirao 
et al. 2009), resulting in fewer cells in the macula sample 
expressing PRKCA. The differential expression of the Mül-
ler cell marker RLBP does not correspond directly to cell 
density, but may reflect differences in volume of the cells 
across the retina (Reichenbach and Bringmann 2013). Peak 
expression of all inner nuclear layer markers was localised 
to the inner nuclear layer apart from CHAT in the paramac-
ula retina, where peak expression occurred more towards 
the inner retina. This is likely to reflect the occurrence of 
displaced CHAT-positive amacrine cells in the RGC layer. 
The marker of photoreceptors (RCVRN) did not show a sig-
nificant difference in expression between the macula and 
paramacula retina, although there was a trend towards lower 
expression in the macula. This corresponds to the differences 
in photoreceptor layer thickness seen in macula and para-
macula human retinal explants (Niyadurupola et al. 2011). 
Planar sectioning revealed peak expression to occur in the 
outer nuclear layer corresponding with the known distri-
bution of photoreceptors. The distribution of cell-specific 
markers in the paramacula and macula retina indicated that 
these techniques are useful to assess distribution of genes of 
interest in the retina. Expression of the selected CDKs was 
therefore investigated in macula and paramacula retina and 
the expression profiles of CDKs of interest evaluated.
CDK5 showed significantly higher expression in the 
macula compared to the paramacula retina. This distribu-
tion indicates that CDK5 may be expressed in ganglion cells, 
since THY1 is the only marker that shows this distribution. 
mRNA profiling in paramacula samples indeed showed 
peak expression of CDK5 to occur in the ganglion cell layer, 
although in the macula, expression was similar throughout 
all retinal layers. This suggests that CDK5 is expressed in 
human RGCs, but that expression also occurs in other cell 
types throughout the retina. This distribution is consist-
ent with CDK5 protein expression in the retina, where the 
highest levels were found in the inner retina (Hayashi et al. 
2000). The functions of CDK5 in the human retina remain 
to be fully elucidated, although there is evidence of a role 
in phototransduction (Hayashi et al. 2000) which could link 
CDK5 inhibition and retinotoxicity. However, dinaciclib had 
the highest binding affinity for CDK5 of the inhibitors tested 
and is not associated with neurotoxicity, indicating that 
CDK5 is not a likely candidate for CDK inhibitor-mediated 
retinotoxicity. Interestingly, research has implicated CDK5 
in RGC death in a rat model of glaucoma, where CDK5 
upregulation was correlated with a significant increase in 
TUNEL positive cells. Roscovine (a CDK5 inhibitor) sig-
nificantly reduced the number of apoptotic RGCs, empha-
sising a potential role for CDK5 in glaucomatous RGC cell 
death (Chen et al. 2011).
CDK11 expression was similar in macula and paramac-
ula retina and planar sectioning revealed peak expression 
of CDK11 in the photoreceptor layer of both macula and 
paramacula samples, although relative differences were 
more noticeable in the paramacula retina. This indicates 
that CDK11 is more highly expressed in photoreceptors 
and that expression of CDK11 could be more associated 
with rod photoreceptors which are the predominant pho-
toreceptors outside of the macula. This distribution, taken 
together with the binding affinity data, implicates CDK11 
as the most likely candidate for mediation of AG-012986 
photoreceptor toxicity. There are two highly homologous 
genes for CDK11 (CDK11A and CDK11B) and from each 
gene there is a full-length protein  (CDK11p110) as well as 
several shorter isoforms including  CDK11p58 (Malumbres 
2014). CDK11 biology is complex, with differing roles 
for different CDK11 isoforms. For example,  CDK11p110 is 
expressed continuously throughout the cell cycle, suggesting 
roles outside of mitotic control, and has been shown to be 
involved in transcriptional regulation and RNA processing 
(Hu et al. 2003), whereas the  CDK11p58 variant is specifi-
cally expressed during the G2/M phase of the cell cycle and 
has roles including centriole duplication and spindle dynam-
ics (Petretti et al. 2006), as well as being associated with cell 
cycle arrest and apoptosis (Rakkaa et al. 2014). CDK11 has 
also been associated with modulation of autophagy, with 
knockdown of CDK11 both inducing autophagy and imped-
ing passage through the autophagic process (Wilkinson et al. 
2011). CDK11 has not previously been studied within the 
retina. However, its expression in neuronal cells has previ-
ously been confirmed and a change in CDK11 cellular distri-
bution has been associated with Alzheimer’s disease (Bajic 
et al. 2011). In addition,  CDK11p58 was found to modulate 
apoptosis in PC12 cells (a rat neuronal cell line) with this 
isoform promoting apoptosis (Liu et al. 2013).
CDK16 expression showed no distinct pattern of expres-
sion between paramacula and macula explants. mRNA 
profiling of macula sections revealed increasing expression 
within the inner nuclear layer before reaching peak expres-
sion towards the inner retina, whereas in paramacula sec-
tions there was peak expression within the inner nuclear 
layer. CDK16, is therefore expressed in the human retina, 
but cellular localization is unclear. CDK16, also known as 
Pctaire 1, is a member of the CDK5 family and has been 
shown to be expressed in brain, testis and skeletal muscle 
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(Besset et al. 1999; Shimizu et al. 2014) and is implicated 
in control of exocytosis (Liu et al. 2006). Knockdown of 
CDK16 has previously been associated with induction of 
apoptosis in melanoma cells (Yanagi et al. 2014); its involve-
ment in retinotoxicity should not be ruled out.
CDK17 expression was similar in the macula and para-
macula retina. mRNA profiling of macula and paramacula 
samples showed low expression in the outer nuclear layer, 
with peak expression in the inner nuclear layer and decreas-
ing expression in the ganglion cell layer, overall displaying 
a similar profile to CHAT and CALB1. These data indicate 
that amacrine and/or horizontal cells possess high levels of 
CDK17. CDK17, also known as Pctaire2, is a poorly char-
acterised protein of the CDK5 family. It is expressed in ter-
minally differentiated neurones with a suggested association 
with cytoskeletal proteins of post-mitotic neurones (Hirose 
et al. 1997), but its role remains undetermined.
CDK18 expression was lower in the macula compared 
to the paramacula retina and similar to the distribution of 
PRKCA (bipolar cells) and RLBP (Müller cells). mRNA pro-
filing of macula and paramacula explants showed minimal 
expression in the outer nuclear layer, high expression in the 
inner nuclear layer and very low expression within the gan-
glion cell layer, again similar to both RLBP and PRKCA. 
CDK18, also known as Pctaire3, that is another poorly char-
acterised member of the CDK5 family. It is expressed in 
neuronal tissue and there is evidence that it plays a role in 
the progression of Alzheimer’s disease, since it is found in 
high concentrations in pathological tissue, and is proposed 
to modulate Tau phosphorylation (Herskovits and Davies 
2006). More recently, it has been shown to prevent accumu-
lated DNA damage and genome instability in response to 
replication stress (Barone et al. 2016).
In terms of distribution in the retina, all of the CDKs 
investigated were expressed in the INL, which could indicate 
expression in Müller cells. It is possible that CDK inhibition 
could affect these cells and since they are the major glial 
cells of the retina, providing essential support for the retinal 
neurons, therefore it was interesting to determine whether 
the pan-CDK inhibitor AG-012986 influences Müller cell 
survival. Exposure of MIO-M1 cells to AG-012986 for 24 h 
revealed a clear dose-dependent increase in cytotoxicity. 
Müller cells are therefore sensitive to inhibition of CDKs by 
AG-012986, with an increase in cell death, and not merely 
a decrease in proliferation. To clarify if the CDKs of inter-
est were expressed in MIO-M1 cells, CDK5, 11, 16, 17 and 
18 expression was measured. CDK11 expression was high 
in MIO-M1 cells. CDKs 5, 16 and 17 were also expressed, 
but expression of CDK18 was extremely low. Interest-
ingly, the binding affinity data of the two neurotoxic CDK 
inhibitors both had a higher affinity for CDK11 than the 
non-toxic inhibitors. CDK11 might therefore be an interest-
ing candidate for further investigation in relation to CDK 
inhibitor-induced death of Müller cells in relation to retinal 
toxicity.
Conclusion
This study aimed to investigate CDK expression in the 
human retina. Whole explant analysis and mRNA profil-
ing from planar sectioned macula and paramacula explants 
revealed CDKs to be differentially expressed. CDK11 was 
predominantly expressed in the photoreceptor layer and the 
two neurotoxic CDK inhibitors tested were more potent 
at CDK11 than the non-neurotoxic CDK inhibitors. This 
research cannot confirm if CDK inhibitor-mediated photore-
ceptor toxicity may or may not occur in humans as has been 
shown in mice, however, CDK11 was found to be highly 
expressed in the human Müller cell line and exposure to the 
CDK inhibitor, AG-012986 caused cytotoxicity. It would be 
of interest to investigate the potential toxicity of AG-012986 
in the ex vivo human retina, as this may clarify any potential 
clinically significant toxicity that the CDK inhibitor may 
possess. Correlation with the expression profiles determined 
here could give a better understanding of the mechanism of 
CDK-mediated retinotoxicity.
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